Oncotec Pharma Produktion GmbH. (6/16/17). "Press Release: Oncotec Celebrates 20 Years of Successful Company History at the Dessau Site". Dessau.

	Region	Dessau
	Country	Germany
	Organisation	Oncotec Pharma Produktion GmbH
	Group	Klocke (Group)
	Organisation 2	Medac Gesellschaft für klinische Spezialpräparate mbH
	Product	contract manufacturing (drugs)
	Product 2	cancer drug
	Person	Rothe, Grit (Klocke Group 201706 Managing Director of Oncotec Pharma Produktion GmbH)

Since its inception in 1997, Oncotec Pharma Produktion GmbH has been producing oncological medicines for the German and foreign market. It is a worldwide reliable partner in the production and development of aseptically produced cytostatics. The company is celebrating the 20th anniversary of the company and looks optimistically into a successful future.

On 04.02.1997 the history of Oncotec begins with the company's entry into the commercial register. At the end of 1999 Oncotec started the production, after the installation of the clean rooms and filling plants. Oncotec is owned by the company medac GmbH, based in Wedel near Hamburg, and the Klocke Group, located in Weingarten / Baden.

The location of Oncotec Pharma Produktion is the BioPharmaPark in the north of Dessau - in close proximity to other renowned pharmaceutical companies such as IDT Biologika GmbH. At the central location synergies and the shared infrastructure are used.

In the last few years Oncotec has grown steadily. The number of employees increased from previously 3 to 250 at present. More than half of the employees work in production, about a quarter in quality control. The employees are characterized by a long-term working relationship, a high level of experience and the highest quality standards.

The core business of Oncotec is the development and production of cytotoxic drugs as contract manufacturing for various clients. At the beginning of the company's history, small batches of selected products were produced in vials and syringes on 2 filling lines. In the course of time, the product spectrum and the quantities produced - particularly after investments in 2007 and 2011 in further filling lines - were significantly increased. Today, Oncotec offers its customers a full service for the entire value chain - from development through market launch to commercial production.

"Our national and international customers value Oncotec for the production of products in the same high quality and for the extensive know-how of our highly qualified employees," says Dr. Grit Rothe, Managing Director of Oncotec. Thanks to the FDA certification, which has been issued again in 2014, Oncotec is also able to supply the US market.

"We are continuously investing in the future of Oncotec and thus ensuring sustainable growth for the region. We are currently optimally equipped for the upcoming production of innovative special products." summarizes Dr. Grit Rothe the current situation of the company. "We are thus expanding our range of future-oriented jobs for the region."

Next year, Oncotec will implement a robot line for filling, including freeze drying, of innovative cytostatics. The production start is planned for the fourth quarter of 2018. To date, Oncotec has performed a semi-automatic inspection of vials and a manual screening of syringes as the last step in the production process. As of the second quarter of 2018, the visual inspection will be completed by a semi-automatic and fully automatic inspection in the newly created Inspection Competence Center. A second building was acquired, refurbished and expanded for the above-mentioned equipmment. The total investment volume is 32 million Euros.

"Today the owners and management look forward to the achievements of the past few years and celebrate this with partners and the employees. In the next week, we will be back on the podium again, "concludes Dr. Grit Rothe.

Contact for more information:

Name: Christin Richter
Phone: +49 34901 8857889
e-mail: christin.richter@oncotec.de

Record changed: 2023-06-05